

# Research Presentations and Publications Made Possible by Funding From the ALS Hope Foundation



## Presentations:

1. Alexander G, Deitch J, Seeburger JL, Israeli D, and Heiman-Patterson TD: Elevated cortical ECF Glutamate in Transgenic mice expressing human mutant (G93A) SOD1. *Neurology* 52: A531-532; 1999.
2. Deitch J, Seeburger JL, Alexander GM, and Heiman-Patterson TD: GLT Dimerization in transgenic mice (G93A) expressing human mutant SOD1. Presented at the 10<sup>th</sup> international Symposium on ALS/NMD Vancouver, CA. November 1999.
3. Alexander, GM, Seeburger JL, Deitch JS, and Heiman-Patterson TD: Changes in Cortical Glutamate levels and its reuptake in a mouse model (G93A) of ALS. *Soc. Neurosci. Abstr.*, 25:1835 1999.
4. Cedarbaum JM Stambler N, Charatan M, Mitsumoto H, Heiman-Patterson T, Olney R: An open label Safety and tolerability study of high-dose subcutaneous recombinant methionyl-human brain derived neurotrophic factor (BDNF ) in 30 patients with ALS. *Neurology* 2000
5. Heiman-Patterson TD, Alexander GM, and Deitch JS: Glutamate is increased but GLT-1 Levels are Unchanged in Mice Expressing G93A Human Mutant SOD1. *Neurology* 2000
6. Heiman-Patterson TD, Rampal N, Brannigan, et al: The spectrum of patients symptoms in ALS and symptom management. *Neurology*, 2001.
7. Del Valle L, Alexander G, Deitch J, and Heiman-Patterson TD: Glial activation in G93A Transgenic Mice. *Neurology* , 2001.
8. Heiman-Patterson, TD, Alexander GA, Deitch J, Perrault M, and Irwin K: Treatment of G93A Mice with Diethylthiocarbamate. *Amyotrophic Lateral Sclerosis and other Motor Neuron Diseases* 2:154, 2001.
9. Forshew D, Heiman-Patterson TD, Bromberg MB: Perceptions in ALS/MND symptom management: Health care providers and patients. *Amyotrophic Lateral Sclerosis and other Motor Neuron Diseases* 2:23, 2001.
10. Cudkowicz M, Shefner J, Schonfeld D et al: Clinical trial of topiramate in subjects with amyotrophic lateral sclerosis. *Amyotrophic Lateral Sclerosis and other Motor Neuron Diseases*, 2:160, 2001.
11. Heiman-Patterson, TD, Deitch JS, Alexander, GM, and Blankenhorn, E: Genetic background and gender influences on phenotype in the G93A SOD1 Transgenic Mouse Model of ALS . *Neurology*, 58:A465, 2002.
12. Goncharova II, McFarland DJ, Heiman-Patterson TD, Vaughn TM, and Wolpaw JR: EEG-based brain computer interface (BCI) communication: reactivity of sensorimotor rhythms in early-stage ALS. *Soc. Neurosci. Abstr.*, Vol 28: 2002.
13. Heiman-Patterson TD, Deitch JS, Blankenhorn EB et al: Background and gender effects on survival in the G93A SOD1 Transgenic Mouse model of ALS. International Symposium on ALS/MND. *Amyotrophic Lateral Sclerosis and Other Motor Neuron Diseases*, Vol 4, Suppl 1:118, 2003.
14. Alexander GA, Irwin K, Byers N, Deitch J and Heiman Patterson TD: Effect of transgene copy number on the G93A Transgenic Mouse Model. *Neurology*, 2004.
15. Ciechoski MA, Heiman-Patterson TD: Differences in Intimacy in Non-ventilator and Ventilator Dependent Persons. , Abstract, International Symposium on ALS/MND. *Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2): 2004.
16. Harris DR, Heiman-Patterson T, Amin M, Cassell S: Quantitative Sensory Testing in the Assessment of Deglutition and Laryngeal Sensory Dysfunction in a Subset of Amyotrophic Lateral Sclerosis (ALS) Patients. International Symposium on ALS/MND. *Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2), 30-31, 2004.

17. Heiman-Patterson T, Deitch J, Alexander GA, Erwins K, Byers N, Toman I, Blankenhorn EP: Genetic Loci Linked to Phenotype in the G93A SOD1 Mouse. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2), 81, 2004.
18. Hyman BA, Sherman M, Deboo A, Mitchell M, Carlson D, Heiman-Patterson T: Positional Changes in Forced Vital Capacity (FVC) in Bulbar vs. Non-bulbar ALS Patients. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2):121-122, 2004.
19. Heiman-Patterson TD, McFarland DJ, Casbestanig F, Wolpaw JR: Development of an EEG-Based Brain-Computer Interface (BCI) Speller Using P300 for People with ALS: Initial Studies. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2):136, 2004.
20. Goren M, Heiman-Patterson TD, Junker A, et al: Computer access using forehead musculature and brainwave technology in people living with endstage ALS. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2):137, 2004.
21. Heiman-Patterson T, Deitch J, Alexander GA, Erwins K, Byers N, Toman I, Blankenhorn EP: Genetic Loci Linked to Phenotype in the G93A SOD1 Mouse. *Neurology*, 64S:A204-5, 2005.
22. Heiman-Patterson T, Deitch J, Alexander GA, and Cunningham T: Phospholipase A2 is implicated in the inflammatory component of injury in G93A SOD1 Transgenic Mice. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2): ,2005.
23. Feldman S and Heiman-Patterson TD: Introducing Computer Accessibility Options to Individuals with ALS. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2): 2006.
24. Harris D, Amin M, Cassel MS and Heiman-Patterson T: Quantitative Sensory Testing in the Assessment of Laryngeal Sensation in Amyotrophic Lateral Sclerosis (ALS) Patients. *International Symposium on ALS/MND. Amyotrophic Lateral Sclerosis and other Motor Neuron Disorders*, 5(Supp 2): 2006.
25. Heiman-Patterson T, Deitch J, Alexander GA, and Cunningham T: Phospholipase A2 is implicated in the inflammatory component of injury in G93A SOD1 Transgenic Mice. *Neurology*, Suppl S56.002 A386, 2006.

## Publications:

1. Deitch JS, Alexander GM, DelValle L, and Heiman-Patterson TD: GLT-1 Glutamate Transporter Levels are Unchanged in Mice Expressing G93A Human Mutant SOD1. *J. Neurosci.*, **193**:117-126, 2002.
2. Cudkowicz ME, Shefner JM, Schoenfeld DA et al: A randomized, placebo-controlled trial of topiramate in amyotrophic lateral sclerosis. *Neurology*, **61**:456-464, 2003.
3. Alexander G, Deitch J, Seeburger JL, Israeli D, and Heiman-Patterson TD: Elevated cortical ECF Glutamate in Transgenic mice expressing human mutant (G93A) SOD1. *Neurology*, **52**:A531-532; 1999.
4. Alexander GM, Erwin K, Byers N, Deitch J, Blankenhorn E, and Heiman-Patterson TD: Effect of gene copy number on survival in the G93A Mouse Model of ALS. *Brain Res. Mol. Brain Res.*, **130**:7-15, 2004.
5. Shefner JM, Cudkowicz ME, Schoenfeld D<sup>3</sup>, Conrad T, Taft J, Chilton M, Urbinelli L, Zhang, H Pestronk A, Caress J, Sorenson E, Bradley W, Lomen-Hoerth C, Piro E, Rezanian K, Ross M, Pascuzzi R, Heiman-Patterson T, Tandan R, Mitsumoto H, Rothstein, and the NEALS Consortium. A Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis. *Neurology*, **63**, 2004.
6. Sherman MS, Pillai A, Jackson A, Heiman-Patterson T. Standard equations are not accurate in assessing resting energy expenditure in patients with amyotrophic lateral sclerosis *J. Parenter. Enteral. Nutr.*, **28**: 442-446, 2004.
7. Heiman-Patterson TD, Deitch JS, Blankenhorn EB, Erwin K, Perreault M, Alexander B, Byers N, and Alexander GA: Background and Gender Effects on Survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. *J. Neurol. Sci.*, **236**:1-7; 2005.